

## [141] ENILVEX THERAPEUTICS, IMMUNE REBALANCING

### Shmulik Hess, CEO, Enlivex Therapeutics R&D LTD, Israel

- **Investment Rational**

Our clinical development includes multiple clinical milestones with targeted indications and markets encompassing significant promise. In 2017, there were ±25,000 allogeneic transplants per year (USA & EU), post transplantation complications are a significant clinical unmet need. Sepsis affects approximately 1.7 million adults in the United States each year and is considered #3 cause of death following cardiovascular disease and cancer.

- **Business Strategy**

Build a specialized cell immunotherapy company that discovers, develops and commercializes novel cell therapies for the treatment of immune disorders. Key elements of Enlivex's strategy include: Utilize available accelerated regulatory programs for life-saving advanced therapies; Initiate clinical trials in 2019-2020; Seek strategic partnerships during 2019 to explore the increased potential benefit of Enlivex's product candidate for treatment of solid tumors

- **Core Technology**

**Allocetra™** the product is composed of proprietary modified healthy donor mononuclear-enriched cells containing stable early-state apoptotic cells. Enlivex's paradigm shifting therapeutic approach is based on rebalancing of the immune system, by infusing early and stable apoptotic cells (dying cells) into the patient. Apoptotic cells interact with immune cells via well-defined mechanisms causing rebalancing of an uncontrolled immune response

- **Product Profile/Pipeline**

Enlivex has completed a phase IIa study for the prevention of post HSCT complications and has initiated a phase Ib "Prevention of sepsis related organ dysfunction" and upon its completion initiate a phase II study. Subject to regulatory approvals, initiate a clinical trial for the prevention and treatment of complications post HSCT: phase II/III for prevention of complications of transplantations from matched unrelated donors (MUR); and (ii) Phase II for the treatment of GvHD steroid-refractory patients

- **What's Next?**

R&D

Preclinical / Clinicals

Organizational plans

Financial plans

